NASDAQ:OVAS - OvaScience Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.76 +0.01 (+1.33 %) (As of 10/18/2018 04:00 PM ET)Previous Close$0.76Today's Range$0.75 - $0.7952-Week Range$0.66 - $1.64Volume52,500 shsAverage Volume371,647 shsMarket Capitalization$26.12 millionP/E Ratio-0.58Dividend YieldN/ABeta3.38 Company ProfileDiscussionAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email OvaScience, Inc., a fertility company, discovers, develops, and commercializes fertility treatment options for women and families struggling with infertility worldwide. Its patented technology is based on the discovery about the existence of egg precursor (EggPC) cells to transform the treatment landscape for women's fertility. The company offers various fertility treatment options, including OvaPrime treatment to restore a woman's egg production by isolating a woman's own EggPC cells within her ovary to mature in vivo into healthy and fertilizable eggs; OvaTure treatment to mature EggPC cells into fertilizable eggs in vitro or outside the body by eliminating the need for hormone stimulation; and AUGMENT treatment to enhance the fertilization and pregnancy rates by using mitochondria from a woman's own EggPC cells. It also provides OvaXon for the prevention of inherited diseases for human and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts. Receive OVAS News and Ratings via Email Sign-up to receive the latest news and ratings for OVAS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:OVAS CUSIPN/A Webwww.ovascience.com Phone617-500-2802 Debt Debt-to-Equity RatioN/A Current Ratio11.43 Quick Ratio11.43 Price-To-Earnings Trailing P/E Ratio-0.58 Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$290,000.00 Price / Sales93.79 Cash FlowN/A Price / CashN/A Book Value$1.80 per share Price / Book0.42 Profitability EPS (Most Recent Fiscal Year)($1.32) Net Income$-50,970,000.00 Net Margins-11,175.59% Return on Equity-47.19% Return on Assets-42.13% Miscellaneous Employees36 Outstanding Shares35,790,000Market Cap$26.12 million OvaScience (NASDAQ:OVAS) Frequently Asked Questions What is OvaScience's stock symbol? OvaScience trades on the NASDAQ under the ticker symbol "OVAS." How were OvaScience's earnings last quarter? OvaScience Inc (NASDAQ:OVAS) posted its quarterly earnings results on Thursday, August, 9th. The biotechnology company reported ($0.14) EPS for the quarter. The biotechnology company earned $0.08 million during the quarter. OvaScience had a negative net margin of 11,175.59% and a negative return on equity of 47.19%. View OvaScience's Earnings History. When is OvaScience's next earnings date? OvaScience is scheduled to release their next quarterly earnings announcement on Thursday, November 1st 2018. View Earnings Estimates for OvaScience. What price target have analysts set for OVAS? 1 Wall Street analysts have issued 1 year price objectives for OvaScience's stock. Their forecasts range from $15.00 to $15.00. On average, they expect OvaScience's stock price to reach $15.00 in the next twelve months. This suggests a possible upside of 1,873.7% from the stock's current price. View Analyst Price Targets for OvaScience. What is the consensus analysts' recommendation for OvaScience? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OvaScience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OvaScience. What are Wall Street analysts saying about OvaScience stock? Here are some recent quotes from research analysts about OvaScience stock: 1. HC Wainwright analysts commented, "Refocus on Science Should Aid in the Long Term; Reit Buy Incremental progress as the company seeks to capitalize upon its internal expertise in cell biology. On yesterday’s 4Q17 call, the company provided an update on the OvaPrime and OvaTure programs as management pivoted to a R&D-focused strategy. We think the key takeaways are two-fold: (1) the interim data from the first 20 patients in the Phase 1 trial of OvaPrime appear to deliver bittersweet news. The safety data look clean, but no strong signals were observed on the secondary endpoints that could suggest efficacy. As a result, this trial has terminated patient enrollment, and per management, the company will advance OvaPrime directly to a Phase 1b/2a study in 2H18 with an improved cell processing technique to hopefully improve efficacy." (3/16/2018) 2. According to Zacks Investment Research, "OvaScience, Inc. is a life science company focused on the discovery, development and commercialization of new treatments for infertility. Its product includes Augment for the treatment of infertility and Ova Ture used in the creation of mature fertilizable eggs. Ova Science, Inc. is headquartered in Cambridge, Massachusetts. " (1/11/2018) Who are some of OvaScience's key competitors? Some companies that are related to OvaScience include IMMUTEP LTD/S (IMMP), Vernalis (VNLPY), GT Biopharma (GTBP), BELLUS Health (BLUSF), Northwest Biotherapeutics (NWBO), Arcturus Therapeutics (ARCT), Iterum Therapeutics (ITRM), IntelGenx Technologies (IGXT), Axsome Therapeutics (AXSM), NewLink Genetics (NLNK), Cumberland Pharmaceuticals (CPIX), Proteostasis Therapeutics (PTI), Chiasma (CHMA), Alpine Immune Sciences (ALPN) and Medicure (MCUJF). Who are OvaScience's key executives? OvaScience's management team includes the folowing people: Dr. Christopher A. Kroeger, CEO, Pres, Sec. & Director (Age 50)Dr. Michelle Dipp, Co-Founder & Advisor (Age 42)Mr. Jonathan Gillis, Sr. VP of Fin. & Treasurer (Age 37)Dr. Jonathan L. Tilly Ph.D., Co-Founder and Advisor (Age 55)Ms. Katherine Pare Lefeber, VP of Strategy & Operations How do I buy shares of OvaScience? Shares of OVAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is OvaScience's stock price today? One share of OVAS stock can currently be purchased for approximately $0.76. How big of a company is OvaScience? OvaScience has a market capitalization of $26.12 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-50,970,000.00 in net income (profit) each year or ($1.32) on an earnings per share basis. OvaScience employs 36 workers across the globe. What is OvaScience's official website? The official website for OvaScience is http://www.ovascience.com. How can I contact OvaScience? OvaScience's mailing address is 9 FOURTH AVENUE, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 617-500-2802 or via email at [email protected] MarketBeat Community Rating for OvaScience (NASDAQ OVAS)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 248 (Vote Outperform)Underperform Votes: 228 (Vote Underperform)Total Votes: 476MarketBeat's community ratings are surveys of what our community members think about OvaScience and other stocks. Vote "Outperform" if you believe OVAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVAS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 10/18/2018 by MarketBeat.com StaffFeatured Article: How is the S&P 500 index different from the DJIA?